Mitochondrial function and cellular energy: the complete guide

TL;DR

• Exercise is the benchmark - Zone-2 and resistance training outperform every compound on this page for mitochondrial function.
• SS-31 (elamipretide) is the category's only approval - FDA accelerated approval in September 2025, for Barth syndrome only, not for energy, performance or ageing.
• Urolithin A has the best human RCT evidence here - modest and real endurance and biomarker gains rather than transformative ones.
• MOTS-c is investigational - a mitochondrial-derived peptide acting as an exercise signal toward biogenesis and metabolic homeostasis.
• NMN and NR reliably raise blood NAD⁺ - whether that reaches tissue and changes anything functional is the open question.
• SLU-PP-332 is rodent-only with an ERRα-related cancer concern, and Vivre does not offer it.

Educational content, not medical advice. Evidence is tiered honestly; most compounds here are investigational, and one is approved for a single rare disease only. No doses appear. This is a measure-don't-guess field.

Updated August 2026: this hub has been rebuilt around mitochondrial function and cellular respiration, which is the question readers are actually asking. NAD⁺ remains covered in full - it now sits as one topic among several rather than the organising idea.

---

Part of the broader Complete Guide to Peptides.

Every contraction, every thought, every repair enzyme runs on ATP, and the overwhelming majority of it is produced inside mitochondria by oxidative phosphorylation. When that process becomes less efficient - fewer mitochondria, more damage, slower turnover - many tissues underperform at once, which is why mitochondrial dysfunction is recognised as a hallmark of aging rather than a single symptom. That also makes "fix your mitochondria" irresistible marketing, and the reason this space is full of expensive vials promising energy in a bottle. The grounded reality: there are four real levers on the system (train it, build it, repair it, recycle it), a fifth that only supplies raw materials (cofactor precursors, including NAD⁺), the compounds are mostly investigational, the lone FDA approval is for a rare disease - and the single most proven intervention on mitochondrial function is still exercise. This guide maps it honestly. Start anywhere.

Start by problem (most people start here)

• Why am I always tired? (the real causes)
• How to get more energy, naturally
• Shift work, circadian misalignment and metabolic health - when the fatigue and the glucose changes are a timing exposure rather than a cellular one

What this guide covers

Start here - the machinery

• Mitochondria and aging: why your cellular engines matter
• Metabolic flexibility: what it means and how it is measured
• How a mitochondrial diagnosis is made - why "mitochondrial dysfunction" and mitochondrial disease are not the same phrase
• What a biological age test measures - and what it doesn't

Build & repair the machinery

• SS-31 vs MOTS-c - repair the engine or build more?
• Is SS-31 FDA-approved? - the short answer, and the large asterisk
• MOTS-C, the mitochondrial peptide - the exercise-mimetic signal in depth
• MOTS-c, the "exercise mimetic" - evidence and access after the FDA vote - where the label overreaches

Recycle the machinery

• Urolithin A & mitophagy - does Mitopure work?
• Does urolithin A build muscle?
• Spermidine and autophagy
• Senolytics and "zombie cells": where the evidence sits - good biology, human trials still on surrogate markers

Supply the cofactors (the NAD⁺ family)

• Cellular energy and age: what happens to ATP production - where the NAD⁺ decline story holds and where it doesn't
• Does raising the cofactor change cellular energy output? - NMN, NR and the precursor question
• Mitochondrial support without the maximalism - why "more is better" is being walked back
• 5-Amino-1MQ & NNMT inhibition - an elegant mechanism with no human data

The supplement aisle

• CoQ10, PQQ & the mitochondrial supplement aisle
• GlyNAC and the glutathione axis - what glycine and NAC actually do, and how small the human evidence is

The long game (stacks & longevity)

• The NAD⁺ + GHK-Cu + Epitalon "longevity stack": evidence vs hype - the popular three-compound combination, tiered honestly

---

The levers on mitochondrial function - and the honest evidence

Almost everything in this space maps to one of a handful of approaches. The most important column is the last one:

Start here: how cells actually make energy

Fuel from food is broken down through glycolysis and the TCA cycle, which strip electrons and hand them to carrier molecules. Those carriers deliver electrons into the electron transport chain on the inner mitochondrial membrane. The chain uses that energy to pump protons across the membrane, creating a gradient; protons flow back through ATP synthase, and that flow is what physically drives ATP production. Oxygen sits at the end of the chain as the final electron acceptor - which is why cellular respiration and breathing are the same story at different scales.

Age degrades this in three ways at once: accumulated damage to the membranes and complexes, fewer and less efficient mitochondria, and slowing turnover (mitophagy), so damaged units are cleared more slowly. That combination is why the decline reads as such a broad feature of aging. The overview guide lays out the biology and the levers in plain language. Read the full guide at the link.

Build & repair: the mitochondrial peptides

Two very different jobs get lumped together. MOTS-c is a mitochondrial-derived peptide that acts like an exercise signal, nudging the cell toward metabolic homeostasis and biogenesis - fascinating, but investigational. SS-31 (elamipretide) instead tries to repair the machinery by stabilising cardiolipin, a lipid the electron transport chain depends on for efficient assembly; it became the first FDA-approved mitochondria-targeted therapeutic in September 2025 - but under accelerated approval for Barth syndrome only (an ultra-rare disease), explicitly not for energy, performance or anti-aging. That distinction gets misrepresented constantly; it is unpacked in is SS-31 FDA-approved?. And SLU-PP-332, the "exercise in a bottle" molecule, is rodent-only with no human data (and an ERRα-related cancer concern) - which is why it isn't offered. The SS-31 vs MOTS-c deep-dive separates repair from build, mechanism by mechanism. Read the full guides at the links.

Recycle: mitophagy and the supplement aisle

Urolithin A (Mitopure) activates mitophagy - the process that clears worn-out mitochondria so healthier ones can replace them - and is, notably, the mitochondrial compound with the most real human RCT evidence (modest but genuine endurance and biomarker gains); the full urolithin A guide is here. The broader supplement aisle - CoQ10, PQQ, and friends - is honestly tiered here: CoQ10 has a defensible case in specific situations, most of the rest is thin, and exercise still wins. Read the full guides at the links.

Supply: the NAD⁺ cofactor and its precursors

NAD⁺ earns its place in this guide for a specific mechanical reason: it is the electron carrier that accepts electrons in glycolysis and the TCA cycle and delivers them to the electron transport chain. No carrier, no gradient, no ATP. That is the entire basis of the "NAD⁺ and energy" story - and it is also where the marketing overreaches, because in a healthy cell the rate-limiting step in ATP production is usually not cofactor availability. Supplying more raw material does not straightforwardly produce more output from a line that wasn't short of material.

NMN and NR are precursors sold in a tribal "which is better" war that is mostly marketing: the best human data suggest they raise blood NAD⁺ to a broadly similar extent, and the harder question is how much reaches tissue and whether anything functional changes. Three guides cover it: what actually happens to ATP production with age, whether raising the cofactor changes energy output, and why the "more is better" posture is being walked back. Human outcome data for NAD⁺ precursors remains thin relative to the marketing, and we say so throughout. Read the full guides at the links.

The honest hierarchy

If you take one thing from this guide: exercise is the proven intervention on mitochondrial function, and current compounds compare unfavourably to it. Urolithin A has the best human trial evidence and its effects are modest. MOTS-c is investigational. SS-31's approval is for a rare disease, not aging. NAD⁺ precursors are promising but oversold, and their human outcome data is thin. The evidence-based order is train first, measure, then consider the rest under supervision - not the reverse.

Measure, don't guess

Mitochondrial function isn't read off how tired you feel - it's approached through markers and functional capacity (lactate response, VO₂max / Zone-2 performance, fasting insulin, inflammatory and lipid markers), interpreted by a clinician against a baseline. Chasing a "mito stack" with no baseline is guessing. The first step is data, not a vial. On what to measure, there's no clean "mitochondrial score" to buy. And if you're considering a consumer aging test as your baseline, read what a biological age test measures first - the number those tests return is not a readout of cellular energy production.

The same principle has a specific application worth knowing, because it is the single most common way this subject is sold badly: metabolic flexibility - the capacity to switch between burning fat and carbohydrate - is a real, measurable property, and it is not something you can perceive. Every "five signs your metabolism is burning fat" list works by attaching it to sensations that are driven by sleep, stress and caffeine instead. Metabolic flexibility: what it means and how it is actually measured covers what research measures, how far the consumer proxies sit from it, and why the symptom lists fail on their own terms.

The bottom line

Declining mitochondrial function is a real hallmark of aging, and building, repairing and recycling the machinery is a genuine scientific frontier - but the marketing runs far ahead of the evidence. Exercise leads; the compounds are mostly investigational and oversold; SS-31's lone approval is for a rare disease. Approached honestly - benchmark with training, measure first, treat compounds as supervised and evidence-tiered - this is a legitimate longevity lever. Approached via the supplement aisle's promises, it's expensive hope.

Explore it with verified supply. Every Vivre Labs lot is independently tested and the certificate of analysis is published, so you know exactly what is in the vial. Explore SS-31.

Frequently asked questions

What's the best way to improve mitochondrial function? Exercise - Zone-2 cardio and resistance training - is the most proven driver of mitochondrial biogenesis and function, outperforming current supplements and compounds.

Do mitochondrial supplements work? Urolithin A has the strongest human trial evidence and its effects are modest. NAD⁺ precursors (NMN/NR) reliably raise blood NAD⁺, but the tissue benefit is uncertain and oversold. Mitochondrial peptides like MOTS-c are investigational. None replace exercise.

Does more NAD⁺ mean more ATP? Not straightforwardly. NAD⁺ is the electron carrier that feeds the electron transport chain, so it is genuinely required for ATP production - but in a healthy cell the limiting factor is usually not how much cofactor is available. Supplying more raw material doesn't reliably raise output.

Is there an approved mitochondrial drug? SS-31 (elamipretide/Forzinity) became the first FDA-approved mitochondria-targeted therapeutic in 2025 - but only for the rare disease Barth syndrome, not for energy or anti-aging. See is SS-31 FDA-approved?.

Where should I start? With the overview and exercise as the benchmark - then a measured, supervised look at peptides and precursors if appropriate.

---

Educational content, not medical advice. Most compounds here are investigational; SS-31 is approved only for Barth syndrome; SLU-PP-332 has no human data and is not offered by Vivre. This is a measure-don't-guess field - baseline testing and physician interpretation come first. Claims for the Malaysian market are subject to MAB requirements.

Key references

• López-Otín C, et al. The Hallmarks of Aging. Cell. 2013;153(6):1194–1217. · FDA accelerated approval of elamipretide (Forzinity), Sept 2025 (Barth syndrome). · See spoke guides for full primary citations.